Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 132Carcinoma, Transitional Cell 91Carcinoma, Non-Small-Cell Lung 84Urinary Bladder Neoplasms 81Melanoma 75Squamous Cell Carcinoma of Head and Neck 50Prostatic Neoplasms 49Colorectal Neoplasms 41Ovarian Neoplasms 36Stomach Neoplasms 35Triple Negative Breast Neoplasms 33Neoplasm Metastasis 32Uterine Cervical Neoplasms 31Neoplasms 28Kidney Neoplasms 27Breast Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 26Lung Neoplasms 26Pancreatic Neoplasms 23Carcinoma, Hepatocellular 23Esophageal Neoplasms 21Head and Neck Neoplasms 20Endometrial Neoplasms 18Small Cell Lung Carcinoma 16Carcinoma, Merkel Cell 11Mesothelioma 9Cholangiocarcinoma 9Ureteral Neoplasms 8Sarcoma 8Carcinoma, Ovarian Epithelial 8

Interventions

pembrolizumab 1enzalutamide 1ascrinvacumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × pembrolizumab × Genitourinary × Clear all
NCT04158700 2020-02-19

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1/2 Withdrawn
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡